Nifty
:
24414.40
Sensex
:
80746.78
34.80 (0.14%)
105.71 (0.13%)
Nifty
Sensex
:
:
24414.40
80746.78
34.80 (0.14%)
105.71 (0.13%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
1191.80
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1191.00
  •  1209.70
  •  1186.10
  •  1191.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1115974
  •  13373.25
  •  1592.00
  •  1010.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 70,343.79
  • 20.15
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 71,594.95
  • 0.37%
  • 2.22

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.82%
  • 0.44%
  • 5.47%
  • FII
  • DII
  • Others
  • 15.33%
  • 23.65%
  • 3.29%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.12
  • 4.66
  • 7.33

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.59
  • 3.73
  • 5.91

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.25
  • 2.10
  • 6.21

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.90
  • 16.33
  • 20.37

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.43
  • 2.06
  • 1.86

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.86
  • 9.44
  • 9.63

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
54.16
64.34
78.34
80.54
P/E Ratio
22.59
19.02
15.62
15.19
Revenue
28705
31445
34758
36845
EBITDA
5843
6758
7750
7921
Net Income
3173
3764
4554
4827
ROA
7.5
8.5
9.6
8.6
P/B Ratio
2.4
2.18
1.94
1.73
ROE
11.2
11.98
12.99
12.03
FCFF
-315.62
2656.7
3445.76
4152.97
FCFF Yield
-0.44
3.71
4.81
5.8

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
7,978.52
7,351.78
8.53%
7,796.07
7,219.42
7.99%
7,567.02
6,850.52
10.46%
7,580.15
6,472.96
17.10%
Expenses
6,400.54
5,750.47
11.30%
6,229.93
5,845.98
6.57%
5,947.45
5,699.15
4.36%
5,907.34
5,470.78
7.98%
EBITDA
1,577.98
1,601.31
-1.46%
1,566.14
1,373.44
14.03%
1,619.57
1,151.37
40.66%
1,672.81
1,002.18
66.92%
EBIDTM
19.78%
21.78%
20.09%
19.02%
21.40%
16.81%
22.07%
15.48%
Other Income
157.29
162.52
-3.22%
136.00
186.98
-27.26%
220.93
116.33
89.92%
135.62
134.91
0.53%
Interest
118.48
75.55
56.82%
112.70
68.18
65.30%
111.04
56.55
96.36%
89.43
55.60
60.85%
Depreciation
418.53
423.27
-1.12%
382.28
417.50
-8.44%
404.18
326.56
23.77%
354.33
345.57
2.53%
PBT
1,198.26
1,265.01
-5.28%
1,207.16
1,074.74
12.32%
1,325.28
814.84
62.64%
1,242.56
735.92
68.84%
Tax
354.28
322.45
9.87%
390.51
323.70
20.64%
405.67
242.32
67.41%
322.55
224.15
43.90%
PAT
843.98
942.56
-10.46%
816.65
751.04
8.74%
919.61
572.52
60.62%
920.01
511.77
79.77%
PATM
10.58%
12.82%
10.48%
10.40%
12.15%
8.36%
12.14%
7.91%
EPS
14.56
15.98
-8.89%
14.07
12.92
8.90%
15.69
9.74
61.09%
15.51
8.64
79.51%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
30,921.76
29,001.87
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
Net Sales Growth
10.85%
16.68%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
 
Cost Of Goods Sold
12,659.24
11,348.78
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
Gross Profit
18,262.52
17,653.09
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
GP Margin
59.06%
60.87%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
Total Expenditure
24,485.26
23,158.87
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
Power & Fuel Cost
-
826.03
842.63
626.86
589.28
587.68
556.79
470.95
437.14
419.26
359.60
% Of Sales
-
2.85%
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
Employee Cost
-
3,922.94
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
% Of Sales
-
13.53%
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
Manufacturing Exp.
-
3,191.71
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
% Of Sales
-
11.01%
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
General & Admin Exp.
-
1,534.59
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
% Of Sales
-
5.29%
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
Selling & Distn. Exp.
-
1,684.72
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
% Of Sales
-
5.81%
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
Miscellaneous Exp.
-
650.10
698.93
419.58
576.06
529.75
413.24
298.75
203.97
212.65
878.98
% Of Sales
-
2.24%
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
EBITDA
6,436.50
5,843.00
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
EBITDA Margin
20.82%
20.15%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
Other Income
649.84
557.38
290.59
322.58
380.85
191.87
155.32
101.98
115.89
203.80
96.71
Interest
431.65
289.71
140.48
48.64
74.49
305.13
262.60
77.72
66.72
256.70
159.87
Depreciation
1,559.32
1,521.66
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
PBT
4,973.26
4,589.01
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
Tax
1,473.01
1,211.02
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
Tax Rate
29.62%
27.54%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
PAT
3,500.25
3,172.97
1,927.50
2,648.15
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
PAT before Minority Interest
3,503.32
3,168.97
1,927.65
2,647.11
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
Minority Interest
3.07
4.00
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
1.50
4.51
PAT Margin
11.32%
10.94%
7.75%
11.29%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
PAT Growth
26.00%
64.62%
-27.21%
-50.87%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
 
EPS
60.27
54.63
33.19
45.59
92.81
49.25
40.67
41.67
39.54
34.84
27.13

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
29,842.80
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
Share Capital
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.52
29.20
Total Reserves
29,784.21
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
Non-Current Liabilities
1,808.94
866.87
903.10
807.27
555.09
358.13
594.11
102.07
583.85
1,591.60
Secured Loans
2,134.90
618.96
249.21
168.49
0.00
48.88
451.20
177.59
380.10
773.54
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
131.07
0.00
3.81
362.71
587.93
Long Term Provisions
225.70
172.72
171.79
157.11
74.71
46.54
55.86
39.13
23.36
24.35
Current Liabilities
12,199.13
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
Trade Payables
4,454.16
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
Other Current Liabilities
3,070.63
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
Short Term Borrowings
4,168.54
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
Short Term Provisions
505.80
412.13
228.59
382.28
511.72
384.67
294.23
261.36
132.93
218.24
Total Liabilities
43,858.87
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
Net Block
14,492.79
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
Gross Block
23,447.77
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
Accumulated Depreciation
8,952.24
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
Non Current Assets
19,653.24
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
Capital Work in Progress
3,868.72
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
Non Current Investment
321.65
391.74
618.30
431.22
554.69
360.20
311.52
245.85
122.94
0.14
Long Term Loans & Adv.
714.55
794.00
575.33
658.44
378.34
396.64
261.91
256.48
236.56
455.27
Other Non Current Assets
255.53
67.39
37.52
53.03
36.61
38.62
86.93
81.29
32.24
30.25
Current Assets
23,771.92
21,459.91
18,043.59
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
Current Investments
50.58
151.00
378.85
159.79
0.02
0.02
0.02
0.02
0.02
19.65
Inventories
9,808.23
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
Sundry Debtors
4,816.74
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
Cash & Bank
6,278.30
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
Other Current Assets
2,818.07
554.71
393.95
601.29
1,555.31
2,715.72
1,977.28
1,596.81
831.25
659.57
Short Term Loans & Adv.
2,298.62
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
Net Current Assets
11,572.79
9,966.13
9,887.61
9,158.46
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
Total Assets
43,425.16
39,126.74
33,554.03
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
2,434.52
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
PBT
4,379.99
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
Adjustment
1,496.24
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
Changes in Working Capital
-1,675.07
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
Cash after chg. in Working capital
4,201.16
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,766.64
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4,255.95
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
Net Fixed Assets
2,277.63
-503.75
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
Net Investments
-5,288.07
-1,521.01
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
Others
-1,245.51
-1,952.99
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
Cash from Financing Activity
800.42
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
Net Cash Inflow / Outflow
-1,021.01
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
Opening Cash & Equivalents
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
Closing Cash & Equivalent
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
509.35
458.10
419.46
374.29
287.16
237.08
199.36
159.96
124.50
88.29
ROA
7.63%
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
ROE
11.18%
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
ROCE
13.76%
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
Fixed Asset Turnover
2.84
2.95
3.24
3.73
4.12
4.36
2.44
2.96
2.79
2.55
Receivable days
28.34
30.42
28.69
29.37
29.85
29.56
64.66
89.16
106.53
91.84
Inventory Days
55.92
57.65
63.29
62.82
57.72
59.64
112.70
101.43
100.27
88.91
Payable days
133.88
117.74
108.60
111.03
53.30
58.56
67.77
75.73
81.70
67.49
Cash Conversion Cycle
-49.62
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
113.25
Total Debt/Equity
0.21
0.18
0.10
0.23
0.33
0.50
0.41
0.36
0.69
0.86
Interest Cover
16.12
19.60
70.34
100.33
13.32
12.76
42.66
46.80
11.69
14.56

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Aurobindo Pharma’s arm gets USFDA's nod to manufacture, market Dasatinib tablets
    23rd Apr 2025, 14:41 PM

    The product is expected to be launched in Q1FY26

    Read More
  • Aurobindo Pharma gets USFDA’s nod to manufacture, market Rivaroxaban Tablets USP
    14th Apr 2025, 09:44 AM

    The product will be launched in Q1FY26

    Read More
  • USFDA concludes inspection at Raleigh plant of Aurobindo Pharma’s arm
    12th Apr 2025, 12:18 PM

    At the conclusion, the USFDA issued a Form 483 with 11 observations

    Read More
  • Aurobindo Pharma’s arm gets marketing authorization for Dyrupeg
    7th Apr 2025, 11:30 AM

    Earlier in January 2025, the Committee for Medicinal Products of European Medicines Agency had adopted positive opinion recommending the approval of Dyrupeg

    Read More
  • Aurobindo Pharma acquires 80% stake in Tergene Biotech
    1st Mar 2025, 12:31 PM

    Tergene has become a direct subsidiary of the company

    Read More
  • USFDA completes inspection at Andhra Pradesh facility of Aurobindo Pharma’s arm
    19th Feb 2025, 10:10 AM

    The inspection concluded with 5 observations

    Read More
  • Aurobindo Pharma to commence supplies to Europe from China facility from April
    17th Feb 2025, 11:10 AM

    The company expects good traction coming out of the China plant over the next 2-3 years

    Read More
  • Aurobindo Pharma’s arm gets marketing authorization for Zefylti
    14th Feb 2025, 11:38 AM

    The company has received marketing authorization from The European Commission

    Read More
  • Aurobindo Pharma reports 10% fall in Q3 consolidated net profit
    7th Feb 2025, 14:39 PM

    Total consolidated income of the company increased by 8.27% at Rs 8135.81 crore for Q3FY25

    Read More
  • Aurobindo Pharma - Quarterly Results
    6th Feb 2025, 19:56 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.